🔎 Trials Near Me

Domov › Crohnova bolezen › North Carolina

Klinične študije za Crohnova bolezen v North Carolina

20 študij za Crohnova bolezen išče udeležence na lokacijah v North Carolina.

Mesta v North Carolina

Uradno besedilo študije (angleško)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • University of North Carolina Medical Center ( Site 5034), Chapel Hill
  • Atrium Health Gastroenterology MMP ( Site 5105), Charlotte
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Digestive Health Partners /ID# 280490, Asheville
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte
  • Carolina Digestive Diseases, Greenville
  • Piedmont Healthcare, Statesville
  • in še 1
Vključevanje udeležencevFaza 4
Starost 18–80 · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT06581328

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • Digestive Health Partners - Biltmore Office /ID# 265539, Asheville
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06548542

A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Charlotte Gastroenterology and Hepatology, PLLC, Charlotte
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07499232

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • University of North Carolina, Chapel Hill
  • Atrium Health, Charlotte
Vključevanje udeležencevFaza 2/3
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT07196722

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Coastal Research Institute - Fayetteville, Fayetteville
Vključevanje udeležencevFaza 3
Starost 18–70 · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
  • OnSite Clinical Solutions-Site Number: 8400051, Charlotte
  • Duke University Medical Center-Site Number: 8400093, Durham
  • in še 3
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • UNC Hospitals, The University of North Carolina at Chapel Hill-Site Number: 8400074, Chapel Hill
  • Cross Creek Medical Clinic-Site Number: 8400057, Fayetteville
Vključevanje udeležencevFaza 3
Starost 16–80 · Vsi spoli · Posodobljeno 23. sep. 2026 · NCT07184944

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  • Cross Creek Medical Clinic, Fayetteville
  • Peters Medical Research, High Point
  • Wake Research Associates, Raleigh
Vključevanje udeležencevFaza 2
Starost 18–85 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06226883

A Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically

  • University of North Carolina at Chapel Hill, Chapel Hill
Vključevanje udeležencevFaza 4
Starost 18 in več · Ženske · Posodobljeno 28. avg. 2026 · NCT07654751

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  • University of North Carolina Hospital, Chapel Hill
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 28. avg. 2026 · NCT07577843

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • University of North Carolina, Chapel Hill
  • Atrium Health Center for Gastroenterology and Surgery, Charlotte
  • Wake Forest School of Medicine, Winston-Salem
Vključevanje udeležencevOpazovalna študija
Starost 18 in več · Vsi spoli · Posodobljeno 5. avg. 2026 · NCT07237516

Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)

  • University of North Carolina at Chapel Hill, Chapel Hill
Vključevanje udeležencev
Starost 18–44 · Ženske · Posodobljeno 14. jul. 2026 · NCT07337902

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • Univ NC Chapel Hill /ID# 262198, Chapel Hill
Vključevanje udeležencevFaza 3
Starost 2–17 · Vsi spoli · Posodobljeno 24. jun. 2026 · NCT06332534

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Levine Children's, Charlotte
Vključevanje udeležencevFaza 4
Starost 6–17 · Vsi spoli · Posodobljeno 27. maj 2026 · NCT05781152

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

  • University of North Carolina at Chapel Hill, Chapel Hill
  • Atrium Health, Charlotte
  • Duke Health System, Durham
Vključevanje udeležencevOpazovalna študija
Starost 1–18 · Vsi spoli · Posodobljeno 17. apr. 2026 · NCT07198113

A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

  • Investigational Site Number: 8400003, Chapel Hill
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 27. mar. 2026 · NCT06958536

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, High Point
  • Mirador Therapeutics Selected Site, Raleigh
Vključevanje udeležencevFaza 2
Starost 18–80 · Vsi spoli · Posodobljeno 12. mar. 2026 · NCT07113522

Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

  • Evidera, a PPD Business Unit /ID# 238688, Morrisville
Vključevanje udeležencevOpazovalna študija
Vse starosti · Ženske · Posodobljeno 17. jul. 2025 · NCT04846959

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.